Circassia (LON: CIR) is a rare example of a small drug maker with a plan B for when drugs trials go wrong. That plan B (use its strong commercial platform to sell respiratory drugs globally) has now landed it with a second drug approval in the US and a label expansion which leaves its first US drug as the best-in-class for patients with chronic obstructive pulmonary disease (COPD). It has been ten months since Circassia filed for approval and the group’s chief executive Steve Harris was all ready to enjoy a well-earned holiday when both approvals came through on Friday. But he was still able to take some time out from his break to talk me through the good news.
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.